2023
DOI: 10.3389/fphar.2023.1291922
|View full text |Cite
|
Sign up to set email alerts
|

From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge

Jialun Zhang,
Peining Zhu,
Siyu Li
et al.

Abstract: The study of trimethylamine oxide (TMAO), a metabolite of gut microbiota, and heart failure and chronic kidney disease has made preliminary achievements and been summarized by many researchers, but its research in the field of cardiorenal syndrome is just beginning. TMAO is derived from the trimethylamine (TMA) that is produced by the gut microbiota after consumption of carnitine and choline and is then transformed by flavin-containing monooxygenase (FMO) in the liver. Numerous research results have shown that… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 131 publications
0
1
0
Order By: Relevance
“…On the other hand ( Wu et al, 2023 ), reviewed the pathogenic mechanism of Immune checkpoint inhibitors-induced cardiotoxicity and evaluated the commonly used cardio-protective drugs. Finally ( Zhang et al, 2023 ), reviewed the gut microbiota product, trimethylamine oxide (TMAO), and its link to cardio pathology, renal pathology, and cardio-renal syndrome.…”
mentioning
confidence: 99%
“…On the other hand ( Wu et al, 2023 ), reviewed the pathogenic mechanism of Immune checkpoint inhibitors-induced cardiotoxicity and evaluated the commonly used cardio-protective drugs. Finally ( Zhang et al, 2023 ), reviewed the gut microbiota product, trimethylamine oxide (TMAO), and its link to cardio pathology, renal pathology, and cardio-renal syndrome.…”
mentioning
confidence: 99%